--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-26-087601" form_type: "8-K" ticker: "VYNE" cik: "0001566044" company_name: "VYNE Therapeutics Inc." filed_at: "2026-07-28T21:11:31+00:00" generated_at: "2026-07-28T21:14:14.649744+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Yarrow Bioscience completes reverse merger with VYNE; Yarrow stockholders own 97% of combined company ## Summary - VYNE valued at $8.5M, Pre-Merger Yarrow at $272.9M; exchange ratio 0.7171 shares of new co per Yarrow share. - Pre-Merger Yarrow stockholders own ~97% of combined company; VYNE stockholders ~3%. - VYNE paid $17.3M cash dividend ($0.40242/share) to its stockholders prior to close. - New board and officers appointed: CEO Rebecca Frey, CFO Tyler Zeronda, and four other C-suite; board of six members. - Pre-Merger Yarrow raised $200M in total: $100M Series A preferred and $100M PIPE pre-closing. ## SEC filing metadata - accession: 0001104659-26-087601 - form_type: 8-K - ticker: VYNE - cik: 0001566044 - company_name: VYNE Therapeutics Inc. - filed_at: 2026-07-28T21:11:31+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/tm2620687d3_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-26-087601 - JSON: https://secwatch.observer/filing/0001104659-26-087601.json - Plain text: https://secwatch.observer/filing/0001104659-26-087601.txt ## Key facts - Executive change Rebecca Frey was appointed as Chief Executive Officer at VYNE Therapeutics Inc.. - Action: appointed - Role: Chief Executive Officer source text: the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm - Executive change Steven Ryder was appointed as Chief Medical Officer at VYNE Therapeutics Inc.. - Action: appointed - Role: Chief Medical Officer source text: the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm - Executive change David Domzalski resigned as President and Chief Executive Officer at VYNE Therapeutics Inc.. - Action: resigned - Role: President and Chief Executive Officer source text: each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026 evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm - Executive change Mutya Harsch resigned as Chief Legal Officer and General Counsel at VYNE Therapeutics Inc.. - Action: resigned - Role: Chief Legal Officer and General Counsel source text: each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026 evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm - Executive change Iain Stuart resigned as Chief Scientific Officer at VYNE Therapeutics Inc.. - Action: resigned - Role: Chief Scientific Officer source text: each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026 evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm - Executive change Tyler Zeronda was appointed as Chief Financial Officer at VYNE Therapeutics Inc.. - Action: appointed - Role: Chief Financial Officer source text: the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm - Executive change Rachael Alford was appointed as Chief Operating Officer at VYNE Therapeutics Inc.. - Action: appointed - Role: Chief Operating Officer source text: the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D. as the Company's Chief Operating Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm - Executive change Lori Payton was appointed as Chief Development Officer at VYNE Therapeutics Inc.. - Action: appointed - Role: Chief Development Officer source text: the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.